In a new blog post, Cato Institute senior fellow Michael F. Cannon says President Trump’s latest executive order on drug pricing crosses into dangerous territory: government-imposed price controls.
“Trump’s executive order is an attempt to impose government price controls on pharmaceuticals,” writes Cannon, warning that it threatens drugmakers with coordinated federal action if they don’t meet price targets. “It’s a laundry list of coercive actions.”
If you’d like to speak with Cannon about this, please feel free to reach out to esalamon@cato.org
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.